[1]王丽辉,徐 佳,姜 晶.沙库巴曲缬沙坦联合螺内酯治疗慢性射血分数降低的心力衰竭临床价值研究[J].陕西医学杂志,2024,(5):675-679.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.022]
　WANG Lihui,XU Jia,JIANG Jing.Value of sacubitril/valsartan combined with spironolactone in the treatment of chronic heart failure with reduced ejection fraction[J].,2024,(5):675-679.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.022]
点击复制

沙库巴曲缬沙坦联合螺内酯治疗慢性射血分数降低的心力衰竭临床价值研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年5期
页码:
675-679
栏目:
药物与临床
出版日期:
2024-05-05

文章信息/Info

Title:
Value of sacubitril/valsartan combined with spironolactone in the treatment of chronic heart failure with reduced ejection fraction
作者:
王丽辉1; 徐 佳2; 姜 晶3
(1.北京中西医结合医院心内科,北京 100039; 2.北京中西医结合医院药剂科,北京 100039; 3.北京中西医结合医院超声科,北京 100039)
Author(s):
WANG Lihui; XU Jia; JIANG Jing
(Department of Cardiology,Beijing Hospital of Integrated Traditional Chinese and Western Medicine,Beijing 100039,China)
关键词:
慢性心力衰竭;  射血分数降低;  沙库巴曲缬沙坦;  螺内酯;  临床价值
Keywords:
Chronic heart failure;  Reduced ejection fraction;  Sacubitril/valsartan;  Spironolactone;  Clinical value
分类号:
R 541.6
DOI:
DOI:10.3969/j.issn.1000-7377.2024.05.022
文献标志码:
A
摘要:
目的:探讨沙库巴曲缬沙坦联合螺内酯治疗慢性射血分数降低的心力衰竭(HFrEF)的临床价值。方法:选取HFrEF患者98例,根据随机数字表法将患者分为血管紧张素Ⅱ受体阻滞剂(ARB)组和血管紧张素受体脑啡肽酶抑制剂(ARNI)组,各49例。两组均给予常规抗心衰及螺内酯治疗,ARB组给予缬沙坦口服,ARNI组给予沙库巴曲缬沙坦口服。比较两组临床疗效、心室重构指标[左室舒张末径(LVEDD)、左室后壁厚度(LVPW)、左室射血分数(LVEF)、室间隔厚度(IVST)和左室收缩末径(LVESD)]、血生化指标[N末端B型利钠肽原(NT-proBNP)、心肌钙蛋白I(cTnI)、肌红蛋白(Myo)、肌酸激酶同工酶(CK-MB)]、运动耐力(6 min步行试验)和心肺运动试验指标[峰值氧耗量(Peak VO2)、无氧代谢阈值时氧耗量(AT)、二氧化碳通气当量(VE/VCO2)]。统计两组治疗期间不良反应及随访1年内心血管不良事件(MACE)发生情况。结果:ARNI组总有效率高于ARB组(P<0.05)。治疗后,两组LVEDD、LVESD、IVST、LVPW较治疗前下降,且ARNI组低于ARB组; LVEF较治疗前增加,且ARNI组高于ARB组(均P<0.05)。治疗后ARNI组NT-proBNP、cTnI、CK-MB低于ARB组(均P<0.05)。治疗后,两组6 min步行距离、Peak VO2、AT较治疗前增加,且ARNI组高于ARB组; VE/VCO2较治疗前下降,且ARNI组低于ARB组(均P<0.05)。两组治疗期间不良反应总发生率及1年内MACE总发生率比较差异无统计学意义(均P>0.05)。结论:沙库巴曲缬沙坦联合螺内酯对慢性HFrEF患者疗效显著,能够改善心功能,逆转心室重构,降低心肺负荷,减轻心肌损伤,提高运动耐力,且安全性较好。
Abstract:
Objective:To explore the clinical value of sacubitril/valsartan combined with spironolactone in the treatment of chronic heart failure with reduced ejection fraction(HFrEF).Methods: A total of 98 HFrEF patients were selected and divided into angiotensin Ⅱ receptor blocker(ARB)group and angiotensin receptor neprilysin inhibitor(ARNI)group with 49 cases in each group according to random number table method.The two groups were given conventional anti-heart failure and spironolactone treatment,and the ARB group was given valsartan orally while the ARNI group was given sacubitril/valsartan.The therapeutic effect and ventricular remodeling indexes(left ventricular end-diastolic diameter [LVEDD],left ventricular posterior wall thickness [LVPW],left ventricular ejection fraction [LVEF],interventricular septal thickness [IVST],left ventricular end-systolic diameter [LVESD]),blood biochemical indexes(N-terminal pro-B-type natriuretic peptide [NT-proBNP],cardiac troponin I [cTnI],myoglobin [Myo],creatine kinase isoenzyme [CK-MB]),exercise endurance(six-minutes walking test)and cardiopulmonary exercise test indexes(peak oxygen consumption [Peak VO2],anaerobic threshold [AT],carbon dioxide ventilation equivalent slope [VE/VCO2])were compared before and after treatment.The adverse reactions during treatment and the occurrence of major adverse cardiovascular events(MACE)within 1 year of follow-up were statistically analyzed.Results: The total effective rate of ARNI group was higher(P<0.05).After treatment,LVEDD,LVESD,IVST and LVPW in both groups were reduced compared to before treatment,and ARNI group was lower than ARB group,and LVEF was higher than that before treatment,and ARNI group was higher than ARB group(all P<0.05).The levels of NT-proBNP,cTnI and CK-MB in ARNI group after treatment were lower compared to ARB group(all P<0.05).After treatment,six-minutes walking distance,Peak VO2 and AT in two groups were increased compared with before treatment,and ARNI group was higher than ARB group(all P<0.05).VE/VCO2 was declined than that before treatment,and ARNI group had lower VE/VCO2(all P<0.05).There were no statistical differences in the total incidence of adverse reactions during treatment and MACE within 1 year between the two groups(all P>0.05).Conclusion:Sacubitril/valsartan combined with spironolactone has a significant effect on patients with chronic HFrEF,which can improve heart function,reverse ventricular remodeling,reduce cardiopulmonary load,alleviate myocardial injury,and improve exercise endurance and has a good safety.

参考文献/References:

[1] 中华医学会老年医学分会心血管疾病学组,《老年慢性心力衰竭诊治中国专家共识》编写组.老年人慢性心力衰竭诊治中国专家共识(2021)[J].中华老年医学杂志,2021,40(5):550-561.
[2] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[3] 陈勇,王洁,杨彤,等.心衰病中西医研究进展[J].陕西中医,2022,43(1):134-136.
[4] 尹玉莲,戴朝晖,蒋庆庆,等.沙库巴曲缬沙坦治疗DCM和ICM致HFrEF患者的临床疗效[J].湖南师范大学学报(医学版),2022,19(5):41-44.
[5] 魏云杰,张密,许海军,等.沙库巴曲缬沙坦治疗高龄射血分数降低心力衰竭患者的临床疗效研究[J].实用心脑肺血管病杂志,2018,26(7):17-20.
[6] MCDONAGH T A,METRA M,ADAMO M,et al.2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J].Eur Heart J,2021,42(36):3599-3726.
[7] 陆滢屹,陈丽雯,柴钰,等.强心方联合沙库巴曲缬沙坦对慢性心力衰竭患者中医症候、心室重构及运动耐力的影响[J].陕西中医,2023,44(8):1052-1055.
[8] 中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2019概要[J].中国循环杂志,2020,35(9):833-854.
[9] ROHDE L E,CLAGGETT B L,WOLSK E,et al.Cardiac and noncardiac disease burden and treatment effect of sacubitril/valsartan:Insights from a combined PARAGON-HF and PARADIGM-HF analysis[J].Circ Heart Fail,2021,14(3):e008052.
[10] WRITING COMMITTEE MEMBERS,ACC/AHA JOINT COMMITTEE MEMBERS.2022 AHA/ACC/HFSA guideline for the management of heart failure[J].J Card Fail,2022,28(5):e1-e167.
[11] 马红红,张启龙,刘娜娜,等.沙库巴曲缬沙坦对原发性高血压的治疗效果及机制研究[J].陕西医学杂志,2023,52(10):1384-1387.
[12] PAVLIDIS G,TSILIVARAKIS D,KATOGIANNIS K,et al.Association of aortic stiffness early post myocardial infarction with left ventricular remodelling[J].Eur J Clin Invest,2024,54(1):e14090.
[13] 杨凯,任斐,江成功,等.沙库巴曲缬沙坦对慢性心力衰竭患者室性心律失常及心率变异性的影响[J].江苏医药,2022,48(9):905-908.
[14] 鲍如意,胡铭,刘建巍,等.血管紧张素受体拮抗剂脑啡肽酶抑制剂对心力衰竭患者肾功能的影响[J].临床心血管病杂志,2021,37(8):700-705.
[15] 白延涛,李燕,石全宝.沙库巴曲缬沙坦对缺血性心肌病病人血流介导血管扩张功能及颈动脉内膜中层厚度的影响[J].中西医结合心脑血管病杂志,2020,18(17):2879-2881.
[16] RODGERS J E.Sacubitril/valsartan:The newest addition to the toolbox for guideline-directed medical therapy of heart failure[J].Am J Med,2017,130(6):635-639.
[17] 孙春全,谢雁鸣,侯恒悦.4832例生脉注射液治疗心力衰竭患者临床特征及联合用药数据挖掘[J].中国药物警戒,2022,19(2):130-133.
[18] 赵大林,王建,谢陈玲.慢性心力衰竭患者血清CK-MB、cTnI与病情严重程度及临床预后的关系[J].临床与病理杂志,2020,40(6):1363-1368.
[19] 申文文,延欢欢.不同类型慢性心力衰竭患者血清肌钙蛋白T和N末端B型钠尿肽原水平变化及临床意义[J].陕西医学杂志,2021,50(9):1109-1113.
[20] 张群英,康娜,唐懿,等.ST2、NT-proBNP在心力衰竭病情进展评估的价值研究[J].标记免疫分析与临床,2021,28(6):1012-1015.
[21] NT-PROBNP临床应用中国专家共识小组.NT-proBNP临床应用中国专家共识[J].中国心血管病研究,2011,9(6):401-408.
[22] 中国康复医学会心血管病专业委员会,中国老年学学会心脑血管病专业委员会.慢性稳定性心力衰竭运动康复中国专家共识[J].中华心血管病杂志,2014,42(9):714-720.
[23] LAU C W,MARTENS P,LAMBEETS S,et al.Effects of sacubitril/valsartan on functional status and exercise capacity in real-world patients[J].Acta Cardiol,2019,74(5):405-412.
[24] 陈会校,李娟,柴巧英,等.沙库巴曲缬沙坦对老年扩张型心肌病继发慢性心力衰竭病人心脏功能及运动耐量的影响[J].中西医结合心脑血管病杂志,2020,18(24):4195-4197.
[25] SRIVASTAVA P K,CLAGGETT B L,SOLOMON S D,et al.Estimated 5-year number needed to treat to prevent cardiovascular death or heart failure hospitalization with angiotensin receptor-neprilysin inhibition vs standard therapy for patients with heart failure with reduced ejection fraction:An analysis of data from the PARADIGM-HF trial[J].JAMA Cardiol,2018,3(12):1226-1231.
[26] SOLOMON S D,MCMURRAY J J V,ANAND I S,et al.Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction[J].N Engl J Med,2019,381(17):1609-1620.

相似文献/References:

[1]王 毅,杨 征.托伐普坦和沙库巴曲缬沙坦钠片对慢性心力衰竭患者心功能及血清钠水平的影响研究[J].陕西医学杂志,2019,(4):470.
[2]李 刚,陈紫凡△.左西孟旦治疗老年慢性心力衰竭患者临床疗效及对患者心功能、肾素-血管紧张素-醛固酮系统的影响[J].陕西医学杂志,2020,49(10):1321.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.032]
　LI Gang,CHEN Zifan..Curative effect of levosimendan in treatment of elderly patients with chronic heart failure and its influence on cardiac function and renin-angiotensin-aldosterone system[J].,2020,49(5):1321.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.032]
[3]申文文,延欢欢.不同类型慢性心力衰竭患者血清肌钙蛋白T和N末端B型钠尿肽原水平变化及临床意义[J].陕西医学杂志,2021,50(9):1109.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.017]
　SHEN Wenwen,YAN Huanhuan.Changes and clinical significance of serum TnT and NT-proBNP levelsin patients with different types of CHF[J].,2021,50(5):1109.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.017]
[4]陈金权,王 蕊.右美托咪定对慢性心力衰竭大鼠的作用及机制研究[J].陕西医学杂志,2022,51(6):664.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.005]
　CHEN Jinquan,WANG Rui.Effect and mechanism of dexmedetomidine on chronic heart failure in rats[J].,2022,51(5):664.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.005]
[5]屈 慧,李 娅.肾功能及电解质水平变异性与慢性心力衰竭患者预后相关性研究[J].陕西医学杂志,2023,52(3):287.[doi:DOI:10.3969/j.issn.1000-7377.2023.03.009]
　QU Hui,LI Ya.Correlation between variability of renal function and electrolyte levels and prognosis of patients with chronic heart failure[J].,2023,52(5):287.[doi:DOI:10.3969/j.issn.1000-7377.2023.03.009]
[6]刘天牧,滕 玥.沉默信息调节因子1/叉头转录因子1通路上调微小RNA-203对慢性心力衰竭大鼠的干预实验研究[J].陕西医学杂志,2023,52(10):1289.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.002]
　LIU Tianmu,TENG Yue.Experimental study on intervention of silent information regulator 1/ forkhead transcription factor 1 pathway up-regulating microRNA-203 in rats with chronic heart failure[J].,2023,52(5):1289.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.002]
[7]张小用,肖仁喜,方 媛.左心室心肌收缩力在体计算方法及其临床应用价值[J].陕西医学杂志,2023,52(11):1526.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.016]
[8]韩 萌,李玉洁,杨国宁,等.人参皂苷通过JAK激酶/信号转导和转录激活因子信号通路抑制慢性心衰大鼠心肌自噬的机制研究[J].陕西医学杂志,2025,54(1):33.[doi:DOI:10.3969/j.issn.1000-7377.2025.01.006]
　HAN Meng,LI Yujie,YANG Guoning,et al.The mechanism of ginsenosides inhibiting myocardial autophagy in chronic heart failure rats through JAK/STAT signaling pathway[J].,2025,54(5):33.[doi:DOI:10.3969/j.issn.1000-7377.2025.01.006]
[9]李玉洁,韩 萌,杨国宁,等.芪参益气滴丸对慢性心衰大鼠线粒体分裂-融合及丝裂原活化蛋白激酶/细胞外信号调节激酶信号通路的影响[J].陕西医学杂志,2025,54(4):465.[doi:DOI:10.3969/j.issn.1000-7377.2025.04.006]
　LI Yujie,HAN Meng,YANG Guoning,et al.Effects of Qishenyiqi dropping pills on mitochondrial fission and fusion and MAPK/ERK1/2 signaling pathway in chronic heart failure rats[J].,2025,54(5):465.[doi:DOI:10.3969/j.issn.1000-7377.2025.04.006]

备注/Memo

备注/Memo:
基金项目:北京市海定区预防医学会科研项目(2019HDPMA08)
更新日期/Last Update: 2024-05-06